Abstract:Christopher W. Course ^ , Sarah J. Kotecha ^ , Sailesh Kotecha ^ Department of Child Health, School of Medicine, Cardiff University, Cardiff, UK ^ ORCID: Christopher W. Course, 0000-0002-7789-2057; Sarah J. Kotecha, 0000-0001-5640-0300; Sailesh Kotecha, 0000-0003-3535-7627. Comment on: Urs RC, Evans DJ, Bradshaw TK, et al . Inhaled corticosteroids to improve lung function in children (aged 6-12 years) who were bornvery preterm (PICSI): a randomised, double-blind, placebo-controlled trial. Lancet Child Adolesc Health 2023;7:567-76. Keywords: Prematurity; bronchopulmonary dysplasia (BPD); spirometry; inhaled corticosteroids; bronchodilators Submitted Oct 12, 2023. Accepted for publication Dec 18, 2023. Published online Jan 15, 2024. doi: 10.21037/tp-23-505 Preterm birth remains a major world-wide health problem (1). Whilst mortality is decreasing especially at the immature gestations, it is apparent that survivors are at increased risk of life-long morbidity including from adverse respiratory outcomes. Our recently updated systematic review demonstrated that, despite advances in neonatal care over the last thirty years, lung function impairments are significant in preterm-born children, adolescents and adults including in those with and without the neonatal lung disease bronchopulmonary dysplasia [BPD, also known as chronic lung disease (CLD) of prematurity] (2). Notably, deficits in lung function are also observed in late preterm-born children who traditionally have not been considered as being at risk of long-term respiratory morbidity (3). The recent guidelines for management of BPD after discharge from the neonatal unit from both the American Thoracic Society (ATS) (4) and European Respiratory Society (ERS) (5) acknowledged the paucity of evidence to guide the long-term, post-discharge management of individuals with a neonatal history of BPD, highlighting the need for studies to assess treatment of prematurity-associated lung disease (PLD). The Respiratory Health Outcomes in Neonates (RHiNO) study has recently demonstrated that there are multiple spirometry phenotypes of PLD, including both fixed and reversible prematurity-associated obstructive lung disease (POLD), prematurity-associated preserved ratio with impaired spirometry (pPRISm) and dysanaptic spirometry patterns, which are differentially associated with early- and current-life factors, including BPD (6). There is an increasing concern that PLD may predispose an individual to the premature development of chronic obstructive pulmonary disease (COPD) in early adulthood (7,8), with implications for quality of life and life expectancy if lung function deficits continue to track into adulthood. Whilst much research focus has concentrated on the mechanism of respiratory morbidity in those with a history of BPD (9,10), it is increasingly apparent that there is a population of preterm-born subjects who develop PLD despite not having had a diagnosis of BPD in the neonatal period (3,11), with impaired spirometry, altered respiratory mechanics and reduced gas diffusion capacity (12). Furthermore, other early life risk factors such as gestational immaturity and intrauterine growth restriction are also strongly associated with later adverse respiratory outcomes (13). Many children with PLD are often given a diagnostic label of asthma (14). However, the mechanisms underlying PLD are likely to be different to those observed in classical asthma which is often predominated by eosinophilic airway inflammation (15) and are only now beginning to be investigated (16-18). Until recently, there have been two previous studies examining inhaled therapies in the management of children with PLD, both studying participants from the pre-/peri-surfactant era ( Table 1 ). Chan et al. performed a double-blind, placebo-controlled cross-over study of fifteen low birth weight children, aged eight years who were born with a mean gestational age of 30.5 weeks. All were born before the routine use of exogenous pulmonary surfactant replacement. The children received twice daily 200 μg of inhaled beclomethasone dipropionate for four weeks or placebo in a cross-over study. There was no significant effect on peak expiratory flow rate (PEFR), forced expiratory volume in one second (FEV 1 ) or airway hyper-responsiveness following treatment (19). In the other study occurring during introduction of exogenous surfactant treatment, Pelkonen et al. studied eighteen children (median gestation at birth of 28 weeks and median of age 10.1 years) who had evidence of reversibility of airway obstruction as assessed by response to short-acting β 2 -agonists. These children received inhaled budesonide (0.8 mg/m 2 /day for 1 month followed by 0.4 mg/m 2 /day for 3 months) over a four-month period. No significant differenc -Abstract Truncated-

Surfactant treatment at birth in a contemporary cohort of preterm infants with bronchopulmonary dysplasia

Treatment of Severe Meconium Aspiration Syndrome with Porcine Surfactant: A Multicentre, Randomized, Controlled Trial

Risk Factors for Bronchopulmonary Dysplasia Infants with Respiratory Score Greater Than Four: a Multi-Center, Prospective, Longitudinal Cohort Study in China

Airway administration of corticosteroids for prevention of bronchopulmonary dysplasia in premature infants: a meta-analysis with trial sequential analysis

Surfactant and budesonide for respiratory distress syndrome: an observational study

A Meta-Analysis of the Effects and Safety of Pulmonary Surfactants Combined with Budesonide in Bronchopulmonary Dysplasia

BPD: Latest Strategies of Prevention and Treatment

[Clinical Efficacy of Pulmonary Surfactant Combined with Budesonide for Preventing Bronchopulmonary Dysplasia in Very Low Birth Weight Infants].

Outpatient clinical care for bronchopulmonary dysplasia: A survey of the BPD collaborative

Polymorphisms of surfactant protein A genes and the risk of bronchopulmonary dysplasia in preterm infants

Can we balance early exogenous surfactant therapy and non-invasive respiratory support to optimise outcomes in extremely preterm infants? A nuanced review of the current literature

Meta-analysis of the efficacy of pulmonary surfactants combined with budesonide for the prevention of bronchopulmonary dysplasia

Evolution of surfactant therapy for respiratory distress syndrome: past, present, and future

Respiratory distress syndrome in VLBW infants: changes in management and outcomes observed by the NICHD Neonatal Research Network

Present and Future of Bronchopulmonary Dysplasia

Hemodynamically significant patent ductus arteriosus profile in preterm neonates (26–34 weeks’ gestation) undergoing surfactant replacement therapy in India: a prospective observational study

Evolving treatment for prematurity-associated lung disease

Hemodynamically significant patent ductus arteriosus profile in preterm neonates (26-34 weeks' gestation) undergoing surfactant replacement therapy in India: a prospective observational study

Analysis of the effectiveness of pulmonary surfactant in the treatment of moderate and severe acute respiratory distress syndrome in infants and toddlers —a multicenter prospective study

Effectiveness and safety of early combined utilization of budesonide and surfactant by airway for bronchopulmonary dysplasia prevention in premature infants with RDS: A meta‐analysis